The Gaithersburg, Md-based drugmaker will use the funding to speed the production of 100 million doses of its vaccine by the beginning of 2021. Novavax has never brought f a product to market, but the candidate employs the same technology as its other experimental vaccines that have gone through late-stage testing.
Results from the vaccine’s May safety trials in Australia are expected to be available in July, and Novavax plans to begin phase 3 efficacy testing during this fall.
“Adding Novavax’s candidate to Operation Warp Speed’s diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” HHS Secretary Alex Azar said in a July 7 news release.
More articles on pharmacy:
Drug lobby sues Minnesota over insulin-pricing law
Regeneron begins late-stage testing of COVID-19 antibody treatment
Early use of hydroxychloroquine reduced COVID-19 deaths, study says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.